Novartis can’t have separate trial on blood pressure drug invalidity claim

Ashurst 2023-08-18 10:04 pm By Cindy Cameronne | Sydney

Please login to bookmark

Novartis has lost its bid to have Pharmacor’s claim that its patent for a blood pressure drug is invalid decided ahead of a main trial where the Swiss pharmaceutical giant will allege the generic drug maker is threatening to infringe its patent.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au